tbuckley/cabot-search huggingface dataset:
Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)
Authors: Matthew M. Heeney, David C. Rees, Mariane De Montalembert, Isaac Odame, R. Clark Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Nadege Pfender, Julie Kanter
Journal: Blood (2021)
CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation
Authors: Camille Abboud, Gautam Borthakur, Scott R. Solomon, Howard A. Burris, Terrence Bradley, JAN Maciej Zaucha, Ewa Lech-Marańda, Krzysztof Brzozka, Tomasz Rzymski, Peter Littlewood, Elie Mouhayar, Setareh Shamsili, Noemi Angelosanto
Journal: Blood (2021)
Increased Platelet S100A8/S100A9 Associated with Vasculitis in Granulomatosis with Polyangiitis (GPA)
Authors: Li Guo, Ben Berger, Jesse W Rowley, Neal D Tolley, Bhanu Kanth Manne, Juan Su, Sikui Shen, Paul D. Crane, Kimberly A Queisser, Aaron C Petrey, Curry L. Koening, Matthew T. Rondina
Journal: Blood (2021)
Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial
Authors: Javier Pinilla Ibarz, Wojciech Jurczak, Suman Kambhampati, Ewa Lech Maranda, Tomasz Wróbel, Jeff P. Sharman, Syed F. Zafar, Marc Hoffmann, Scott F. Huntington, Ryan Jacobs, Osnat Bairey, Chris Rowland, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Owen A. O'Connor, Ian W. Flinn
Journal: Blood (2021)
Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis
Authors: Marc S Sabatine, Brian A Bergmark, Sabina A Murphy, Patrick T O'Gara, Peter K Smith, Patrick W Serruys, A Pieter Kappetein, Seung-Jung Park, Duk-Woo Park, Evald H Christiansen, Niels R Holm, Per H Nielsen, Gregg W Stone, Joseph F Sabik, Eugene Braunwald
Journal: The Lancet (2021)
Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients
Authors: Sarah Gooding, Naser Ansari-Pour, Mohammad H Kazeroun, Kubra Karagoz, Mirian Angulo Salazar, Evelyn Fitzsimons, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William E. Pierceall, Kwee Yong, Paresh Vyas, Anjan Thakurta
Journal: Blood (2021)
Abstract 9492: Ventricular Tachycardia During Cardiopulmonary Exercise Testing in Hypertrophic Cardiomyopathy
Authors: Ibolya Csecs, Darrell B Newman, Marieke Nederend, Kyle W Klarich, Thomas G Allison
Journal: Circulation (2021)

Introduction and Hypothesis: In patients with hypertrophic cardiomyopathy (HCM), ventricular tachycardia (VT) is associated with adverse prognosis. Cardiopulmonary exercise testing (CPET) is part of the standard clinical evaluation in HCM. However, limited data are available on the incidence of VT and other adverse events during CPET in HCM. Methods: We reviewed the Mayo Clinic’s Integrated Stress Center Database for CPETs performed on HCM patients between January 2011 and July 2016. Patients were referred for clinical CPET by a physician, and medications were continued for the test. Electronic medical records were reviewed for clinical information and CPET data. Results: A total of 1,208 CPETs were performed on 976 HCM patients during the study period. Most tests were symptom-limited (94.6%), most common symptom was dyspnea (55%). Despite the relatively high number of patients with a history of VT (10.4%) and/or cardiac arrest (1.6%), there was a low rate of adverse events. Non-sustained VT occurred in 6 patients, most frequently during active recovery (3/6), and 2 of these 6 patients had prior history of VT. A 34 year-old female patient experienced sustained VT degenerating into ventricular fibrillation terminated by ICD shock. One patient had syncope during the test but no arrhythmia. Importantly, none of the patients died within 48 hours of the exercise test. Conclusions: In a large cohort of HCM patients, the incidence of VT or other adverse events was a rare finding during symptom-limited CPET.
Heme Induced Progressive Loss of Endothelial Protein C Receptor Promotes Development of Chronic Kidney Disease in Sickle Cell Disorders
Authors: Rimi Hazra, Qiyang Chen, Danielle Crosby, Diane Lenhart, Roderick Tan, Kang Kim, L. Vijaya Mohan Rao, Solomon Fiifi Ofori-Acquah, Samit Ghosh
Journal: Blood (2021)
Inhibition of Fibroblast Growth Factor-23 (FGF-23) Rescues Bone and Hematopoietic Stem Cell Niche Defects in Beta-Thalassemia, Uncovering the Missing Link between Hematopoiesis and Bone
Authors: Annamaria Aprile, Laura Raggi, Simona Bolamperti, Mariangela Storto, Isabella Villa, Gaia Morello, Sarah Marktel, Claudio Tripodo, Irene Motta, Maria Domenica Cappellini, Alessandro Rubinacci, Giuliana Ferrari
Journal: Blood (2021)
A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to &amp;lt;21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML
Authors: Philip Connor, Linyi Fan, Stanley Gill, Jason E. Hill, Nisha Philipose, David Delgado, Ramon V. Tiu, Dirk Reinhardt
Journal: Blood (2021)
Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients
Authors: Joan How, Kathleen M.E. Gallagher, Yiwen Liu, Ashley DeMato, Katelin Katsis, Rebecca Larson, Mark B. Leick, Donna S. Neuberg, Marcela V. Maus, Gabriela Hobbs
Journal: Blood (2021)
Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma
Authors: Xuehai Wang, Michael Nissen, Deanne Gracias, Manabu Kusakabe, Guillermo Simkin, Gerben Duns, Clementine Sarkozy, Elizabeth Chavez, Gabriela Cristina Segat, Jubin Kim, Aixiang Jiang, Tomohiro Aoki, Rashedul Islam, Christina May, Stacy Hung, Kateryna Tyshchenko, Ryan Brinkman, Martin Hirst, Aly Karsan, Ciara L. Freeman, Laurie H. Sehn, Kerry J. Savage, Jeffrey W Craig, David W. Scott, Christian Steidl, Sohrab P Shah, Andrew P. Weng
Journal: Blood (2021)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732
Authors: Jennifer L. McNeer, Maureen M. O'Brien, Susan R. Rheingold, Meenakshi Devidas, Zhiguo Chen, Deepa Bhojwani, Anurag K. Agrawal, Brent Wood, Eugene Suh, Sarah Alexander, Tamara P. Miller, Olga Militano, Elizabeth A. Raetz, Mignon L. Loh
Journal: Blood (2021)
Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy
Authors: Evandro D. Bezerra, Javier Munoz, Hemant S. Murthy, Arushi Khurana, Radhika Bansal, Madiha Iqbal, Matthew J. Maurer, Matthew A Hathcock, Patrick B. Johnston, Nora Bennani, Jonas Paludo, Yucai Wang, Jose C. Villasboas, Allison C. Rosenthal, Stephen M. Ansell, Thomas E. Witzig, Januario E Castro, Mohamed A. Kharfan-Dabaja, Grzegorz S. Nowakowski, Yi Lin
Journal: Blood (2021)
Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100
Authors: Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson I Gonsalves, Rahma M Warsame, Eli Muchtar, Nelson Leung, Robert A. Kyle, Shaji Kumar
Journal: Blood (2021)
Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy
Authors: Sujith Baliga, Sara Gallotto, Benjamin Bajaj, Jacqueline Lewy, Elizabeth Weyman, Miranda P Lawell, Beow Y Yeap, David E Ebb, Mary Huang, Paul Caruso, Alisa Perry, Robin M Jones, Shannon M MacDonald, Nancy J Tarbell, Torunn I Yock
Journal: Neuro-Oncology (2021)

Survivors of pediatric medulloblastoma experience long-term morbidity associated with the toxic effects of postoperative radiotherapy (RT). Proton RT limits radiation dose to normal tissues thereby reducing side effects of treatment while maintaining high cure rates. However, long-term data on disease outcomes and long-term effects of proton RT remain limited.One hundred seventy-eight pediatric medulloblastoma patients treated with proton RT between 2002 and 2016 at the Massachusetts General Hospital comprise the cohort of patients who were treated with surgery, radiation therapy, and chemotherapy. We evaluated event-free survival (EFS), overall survival (OS), and local control using the Kaplan-Meier method. The cumulative incidence of brainstem injury and secondary malignancies was assessed.Median follow-up was 9.3 years. One hundred fifty-nine patients (89.3%) underwent a gross total resection (GTR). The 10-year OS for the entire cohort, standard-risk (SR), and intermediate/high-risk (IR/HR) patients was 79.3%, 86.9%, and 68.9%, respectively. The 10-year EFS for the entire cohort, SR, and IR/HR cohorts was 73.8%, 79.5%, and 66.2%. The 10-year EFS and OS for patients with GTR/NTR were 75.3% and 81.0% vs 57.7% and 61.0% for subtotal resection (STR). On univariate analysis, IR/HR status was associated with inferior EFS, while both anaplastic histology and IR/HR status were associated with worse OS. The 10-year cumulative incidence of secondary tumors and brainstem injury was 5.6% and 2.1%, respectively.In this cohort study of pediatric medulloblastoma, proton RT was effective, and disease outcomes were comparable to historically treated photon cohorts. The incidence of secondary malignancies and brainstem injury was low in this cohort with mature follow-up.
Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy
Authors: Krishna V. Komanduri, Anton Belousov, Michelle Byrtek, Antonia Kwan, David Perez-Callejo, Chi-Chung Li, David Carlile, Bruce McCall, Tina Nielsen, Emily C. Piccione
Journal: Blood (2021)
Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy
Authors: Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Eileen Regan, Efstathios Kastritis, Meletios A. Dimopoulos, Paul G. Richardson, Giada Bianchi
Journal: Blood (2021)
Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp
Authors: Anna Santarsieri, Katherine Sturgess, Pauline Brice, Tobias F Menne, Wendy Osborne, Thomas Creasey, Kirit M. Ardeshna, Sarah Behan, Kaljit Bhuller, Stephen Booth, Graham P. Collins, Kate Cwynarski, Andrew Davies, Michelle Furtado, Eve Gallop-Evans, Andrew Hodson, Sunil Iyengar, Stephen G Jones, Kim Linton, Nicolas Martinez-Calle, Pamela McKay, Sateesh K Nagumantry, Deirdre O'Mahony, Beth Phillips, Neil Phillips, John F Rudge, Nimish Shah, Gwyneth Stafford, Alex Sternberg, Rachel Trickey, Benjamin J Uttenthal, Nathasha Wetherall, Andrew K McMillan, George A Follows
Journal: Blood (2021)
Milvexian for the Prevention of Venous Thromboembolism
Authors: Jeffrey I. Weitz, John Strony, Walter Ageno, David Gailani, Elaine M. Hylek, Michael R. Lassen, Kenneth W. Mahaffey, Ravi S. Notani, Robin Roberts, Annelise Segers, Gary E. Raskob
Journal: New England Journal of Medicine (2021)

Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxaparin (40 mg once daily). The primary efficacy outcome was venous thromboembolism (which was a composite of asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause). The principal safety outcome was bleeding.Among the patients receiving milvexian twice daily, venous thromboembolism developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg. Among those receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg, as compared with 54 of 252 patients (21%) taking enoxaparin. The dose-response relationship with twice-daily milvexian was significant (one-sided P<0.001), and the 12% incidence of venous thromboembolism with twice-daily milvexian was significantly lower than the prespecified benchmark of 30% (one-sided P<0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively.Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Bristol Myers Squibb and Janssen Research and Development; AXIOMATIC-TKR ClinicalTrials.gov number, NCT03891524.).
Abstract 9452: <sub>Artificial Intelligence for Predicting Human Age in ECG</sub>
Authors: ZHI-XUAN CHUO, Ruey-Kang Chang
Journal: Circulation (2021)

Background: Previous research has shown that age is highly correlated to ECG findings, and machine learning (ML) can be used to predict the age of a patient based on the findings on a 12-lead ECG. We structured a state-of-the-art deep ML model to correlate with age, which may be used to detect changes following the trends. Methods: We composed a 40-layers self-definite ResNet model. The model was trained with 10-second 12-lead ECG of 25,915 records from 23,625 patients. We then validated the accuracy of age prediction using 6,479 records from a separate dataset. Once the model was validated, we tested the model using randomly selected ECG records, including 20 records from a weight loss center and 20 records from cardiology clinic patients. Results: After the model was developed and validated, we tested it on 40 patients with ages 52.2 ±13.7 years, ranging from 17 to 76 years. The mean absolute error (MAE) was 8.0 years and the root mean square error (RMSE) was 9.7 years. Among these 40 patients, 21 patients (52.5%) had ECG-predicted age within 7 years difference from their chronological age. When we selected the age range of 42-75 years old (29 records), the result of MAE decreased to 7.4 years, with 70% of the prediction results within 7 years and the RMSE decreased to 9.1 years. The average difference between chronological and ECG-predicted ages decreased to 3 years when serial recordings of ECG of the same patients were used. Conclusions: Using ML models, ECGs can be used to correlate with a patient’s age and may be useful to track the changes longitudinally. “ECG-predicted age” may be an important measurement to follow the trend for comprehensive health assessment over time.
Patterns of Coronary Artery lesion in a Patient with Chronic Obstructive Pulmonary Disease, Presenting with an Acute Coronary Syndrome
Authors: Ranjit Sharma, Anish Hirachan, Milan Gautam
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Background: This study was designed to evaluate the patterns of coronary artery disease in patients with chronic obstructive pulmonary disease (COPD) presenting with the acute coronary syndrome (ACS). Methods: This was a prospective, observational study, conducted on 69 patients with chronic obstructive pulmonary disease, presenting with acute coronary syndrome undergoing coronary angiogram from September 2017 to March 2021. All patients had undergone coronary angiogram; severity and morphology of lesion as well as the severity of calcium were analyzed. Results: The study showed that 69 patients with COPD who presented with ACS, 58.8% of patients were presented with NSTEMI, 30.2% STEMI and Unstable angina 11%. The average time of presentation after the onset of the symptom was 17.6 hours. 64% of patients were a smoker. Coronary involvement 10% of patients had LM, 50% TVD, 30% DVD, and 10% had SVD. Type a coronary lesion was seen in 5%, Type B in 20%, and Type C in 75% of patients. Mild Coronary calcium was seen in 25%. Moderate calcium was in 40% and severe calcium in 35%. Conclusions: COPD patients presenting with ACS, associated with increased severity of coronary calcium and coronary lesions.
Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis
Authors: Francesca Palandri, Daniela Bartoletti, Elisabetta Abruzzese, Alessandra Iurlo, Massimiliano Bonifacio, Giovanni Caocci, Elena Maria Elli, Giuseppe Auteri, Mario Tiribelli, Nicola Polverelli, Bruno Martino, Maurizio Miglino, Florian H. Heidel, Alessia Tieghi, Giulia Benevolo, Eloise Beggiato, Carmen Fava, Francesco Cavazzini, Novella Pugliese, Gianni Binotto, Costanza Bosi, Monica Crugnola, Emanuela Ottaviani, Christian Di Pietro, Giorgia Micucci, Malgorzata Monika Trawinska, Antonio Cuneo, Monica Bocchia, Mauro Krampera, Fabrizio Pane, Roberto M. Lemoli, Daniela Cilloni, Michele Cavo, Nicola Vianelli, Giuseppe A. Palumbo, Massimo Breccia
Journal: Blood (2021)
Aging-Related Changes in Erythropoietic Activity and Iron Metabolism in a Mouse Model of Congenital Erythrocytosis with Human Gain-of-Function Erythropoietin Receptor
Authors: Barbora Kralova, Ondrej Jahoda, Jihyun Song, Katarina Hlusickova Kapralova, Lucie Sochorcova, Josef T. Prchal, Vladimir Divoky, Monika Horvathova
Journal: Blood (2021)
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
Authors: Julia E. Wiedmeier, Madiha Iqbal, Javier Munoz, Evandro D. Bezerra, Juan Esteban Garcia Robledo, Radhika Bansal, Patrick B. Johnston, Matthew Hathcock, Jeremy T. Larsen, P. Leif Bergsagel, Yucai Wang, Craig B. Reeder, Jose F. Leis, Rafael Fonseca, Jeanne M. Palmer, Rahma M Warsame, Taxiarchis Kourelis, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Shaji Kumar, Urshila Durani, Jose C. Villasboas, Jonas Paludo, N. Nora Bennani, Stephen M. Ansell, Januario E Castro, Mohamed A. Kharfan-Dabaja, Yi Lin, Paschalis Vergidis, Hemant S. Murthy, Allison C. Rosenthal
Journal: Blood (2021)
Orihime Study: Real World Treatment Patterns and Clinical Outcomes of 338 Patients with Acquired Hemophilia a from a Japanese Health Claims Database
Authors: Yoshiyuki Ogawa, Kagehiro Amano, Yukari Matsuo-Tezuka, Norihiro Okada, Yoichi Murakami, Takao Nakamura, Haruko Yamaguchi-Suita, Keiji Nogami
Journal: Blood (2021)
Prostate-Specific Antigen Testing for Prostate Cancer Screening—Is the Message Getting Through?
Authors: Freddie C. Hamdy
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
Authors: Giulia Baciarello, Remy Delva, Gwenaelle Gravis, Youssef Tazi, Philippe Beuzeboc, Marine Gross-Goupil, Emmanuelle Bompas, Florence Joly, Charlotte Greilsamer, Thierry Nguyen Tan Hon, Philippe Barthelemy, Stephane Culine, Jean Francois Berdah, Mathilde Deblock, Raffaele Ratta, Aude Flechon, Caroline Cheneau, Aline Maillard, Geraldine Martineau, Isabelle Borget, Karim Fizazi
Journal: European Urology (2021)
Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity
Authors: William Breen, Jason R. Young, Matthew Hathcock, Roman O. Kowalchuk, Radhika Bansal, Arushi Khurana, N. Nora Bennani, Jonas Paludo, Jose C. Villasboas, Yucai Wang, Stephen M. Ansell, Jennifer Peterson, Patrick B. Johnston, Scott Lester, Yi Lin
Journal: Blood (2021)
Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice
Authors: M.‐E. Marniquet, J. Seneschal, A.‐S. Darrigade, D. Staumont‐Sallé, M. Jachiet, A. Nosbaum, M. Tauber, C. Abasq, M.‐C. Ferrier Le Bouedec, C. Droitcourt, H. Aubert, C. Bernier, A. Soria, N. Raison‐Peyron, F. Tétart, F. Aubin, M. Viguier, A. Valois, I. Kupfer‐Bessaguet, T. Goronflot, S. Barbarot
Journal: British Journal of Dermatology (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2)
Authors: Natalie T. Deuitch, Dan Yang, Pui Y. Lee, Xiaomin Yu, Natalia Sampaio Moura, Oskar Schnappauf, Amanda K. Ombrello, Deborah Stone, Hye Sun Kuehn, Sergio D. Rosenzweig, Patrycja Hoffmann, Cornelia Cudrici, Deborah M. Levy, Elizabeth Kessler, Jennifer B. Soep, Arielle D. Hay, Austin Dalrymple, Yu Zhang, Li Sun, Qiuye Zhang, Xuemei Tang, Yuan Wu, Koneti Rao, Haibo Li, Hong Luo, Yao Zhang, Jon M. Burnham, Manfred Boehm, Karyl Barron, Daniel L. Kastner, Ivona Aksentijevich, Qing Zhou
Journal: Journal of Allergy and Clinical Immunology (2021)